Impact of Race/Ethnicity on Clinical and Genomic Characteristics, Trial Participation, and Genotype-Matched Therapy among Patients with Metastatic Breast Cancer

By sjmartinez • January 28, 2025

Sood R, Niemierko A, Ryan L, Spring L, Moy B, Bardia A, Vidula N. Impact of Race/Ethnicity on Clinical and Genomic Characteristics, Trial Participation, and Genotype-Matched Therapy among Patients with Metastatic Breast Cancer. Clin Cancer Res. 2025 Jan 27. doi: 10.1158/1078-0432.CCR-24-2825. Epub ahead of print. PMID: 39869305.

Tags: Hematology/Oncology, Publications

Osimertinib Plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD

Goldberg SB, Ahn MJ, Baik C, De Castro Carpeño J, Cho BC, de Langen AJ, Fidler MJ, Goldman JW, Grønberg BH, Akamatsu H, Kim SW,[...]

Avutometinib, Abemaciclib, and Fulvestrant in Patients with HR+/HER2- Metastatic Breast Cancer Previously Treated with CDK4/6 Inhibitor: A Single-Arm Phase I Trial

Waks AG, Segui E, Li T, Lipsyc-Sharf M, Kallfelz E, DiLullo M, Patel A, Rahman T, Junkins K, Rahee H, Frey AM, Kelly E, Stalteri[...]

Current Management of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in a Changing Landscape

Lipsyc-Sharf M, Hurvitz SA. Current Management of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in a Changing Landscape. J Clin Oncol. 2026 Jul 13:JCO2600672.[...]